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BACKGROUND: Locally advanced rectal carcinoma has a poor prognosis. However,
since the introduction of preoperative radiotherapy, the outcome of patients with
rectal carcinoma has been reported to have improved. Nevertheless, to the au-
thors’ knowledge few data are available regarding the histopathologic response to
radiotherapy as assessed on surgical specimens as a potential predictive factor for
outcome.
METHODS: To estimate the effect of radiotherapy on rectal carcinoma, the authors
retrospectively reviewed the surgical specimens of 102 patients with T3-4, N0 or
 N1 rectal carcinoma and 1 patient with T2 but N1 rectal carcinoma. All patients
were treated preoperatively with a hyperfractionated accelerated radiotherapy
schedule in a prospective protocol (Trial 93-01). Using a standardized approach,
tumor regression was graded using a system that varies from Grade 1 (tumor
regression Grade [TRG] 1) when complete tumor regression is observed to Grade 5
(TRG5) when no tumor regression is observed.
RESULTS: Radiotherapy resulted in tumor downstaging in 43% of the patients.
There were 2 pT1 tumors (2%), 21 pT2 tumors (20%), 66 pT3 tumors (64%), and 14
pT4 tumors (14%) after treatment. Regional lymph nodes were involved in 55
patients (53%). None of the patients demonstrated a complete tumor regression
after radiotherapy, but in 79% of the specimens a partial tumor regression was
observed (TRG1: 0%; TRG2: 20%; TRG3: 39%; TRG4: 20%; and TRG5: 21%). The
median actuarial overall survival (OS) and disease-free survival (DFS) were 52
months. Actuarial local recurrence rates at 2 years and 5 years were 6.4% and 7.6%,
respectively. Univariate analysis showed the actuarial DFS to be significantly lower
in patients with lymph node metastases (P  0.0004) and advanced pT stages
(pT3-4) (P  0.03). A favorable outcome for OS, DFS, and local control was
observed in patients with TRG2-4 (i.e., responders) compared with patients with
TRG5 (i.e., nonresponders), but also in patients with low residual tumor cell
density (TRG2, 3, and 4). On multivariate analysis, TRG remained an independent
prognostic indicator for local tumor control.
CONCLUSIONS. Tumor regression as well as residual tumor cell density were found
to be predictive factors of survival in rectal carcinoma patients after preoperative
radiotherapy. Even after preoperative radiotherapy, the pathologic stage of the
surgical specimen remained a prognostic factor. The use of a standardized ap-
proach for pathologic evaluation must be implemented to allow comparison be-
tween the results of various treatment approaches. Cancer 2002;94:1121–30.
© 2002 American Cancer Society.
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Colorectal carcinoma is a significant cause of mor-bidity and mortality in Western populations. Rec-
tal carcinoma is characterized by a high incidence of
local recurrence (20 –70%), regional lymph node me-
tastases, and distant metastases.1,2 Major improve-
ments have been made in the surgical control of local
disease since the introduction of the so-called total
mesorectal excision.3,4 Nevertheless, the incidence of
local recurrence remains high (10 –30%).5–10 Moder-
ate- to high-dose neoadjuvant preoperative radiother-
apy has been shown to induce tumor regression and
downstaging, thus significantly improving local con-
trol.7,10 –18 The role of preoperative radiotherapy in
survival remains controversial, with some studies re-
porting a minimal effect,17,19,20 whereas in other trials
a significant impact has been shown.7–9,13,14,16,21–23 In
a recent meta-analysis, it was suggested that preoper-
ative radiotherapy significantly improves overall and
cancer specific survival but much more in patients
with Dukes Stage B and C tumors than in patients with
Dukes Stage A tumors.24 However, to our knowledge,
the histopathologic characteristics of the response of
rectal carcinoma to ionizing irradiation have been
poorly documented, and the results reported from
different studies often are contradictory. This can be
explained by the heterogeneity in clinical staging pro-
cedures and by treatment-related factors. The lack of a
standardized approach toward the pathologic assess-
ment of tumor response certainly is another source of
discrepancy.
We have developed an accelerated irradiation
schedule that completes the treatment in 2.5 weeks,
with the intention to counter tumor repopulation dur-
ing treatment and to reduce the incidence of late
complications by using hyperfractionation (i.e., reduc-
ing the dose per fraction).25 This hyperfractionated
and accelerated radiotherapy (HART) schedule imme-
diately is followed by surgery to keep the overall treat-
ment time as short as possible. HART has been tested
in patients with locally advanced rectal carcinoma,
(i.e., T3 and T4 rectal carcinomas or any T classifica-
tion providing evidence of lymph node involvement)
(Trial 93-01). We have demonstrated previously that
preoperative HART is feasible and is associated with
significantly lower toxicity compared with postopera-
tive radiotherapy.25,26 Based on this experience, a
Phase II trial has been initiated.
The purpose of the current study was to assess the
histologic response by a standardized and reproduc-
ible method and to determine its prognostic value in a
series of patients with locally advanced rectal carci-
noma who were prospectively treated with HART.
MATERIALS AND METHODS
Patients
This study included 103 successive patients with lo-
cally advanced rectal carcinoma (T3-4 or any T clas-
sification but N positive) who were eligible for Trial
93-01 and were treated with HART in Lausanne, Swit-
zerland between 1992 and 1998.25,26 The ages of the
patients ranged from 28 – 85 years (median age, 63
years) and the gender ratio (female/male) was 1.2.
Prior to the initiation of treatment, all patients under-
went a rectal biopsy, complete clinical examination,
blood count, assessment of renal and hepatic func-
tion, and carcinoembryonic antigen (CEA) assay. Dis-
tant metastatic disease was excluded by chest X-ray,
abdominal ultrasound, and thoracoabdominal com-
puted tomography (CT) scan. The assessment of the
local extent of the tumor was based on digital rectal
examination, and completed by rectal ultrasound and
CT scan. In total, 102 patients were classified as having
T3-4 tumors. In 27 patients (26%) we suspected lymph
node involvement based on rectal ultrasound or CT
findings. One patient was classified as having T2 N1
disease. All patients were irradiated with a linear ac-
celerator with a minimal accelerating potential of 6
megavolts. The dose per fraction was 1.6 grays (Gy)
and the interfraction interval was at least 6 hours. The
total dose was increased to 41.6 Gy in 26 fractions
given over 2.5 weeks. The interval between the end of
radiotherapy and surgical resection was kept as short
as possible, usually within 6 days (median of 5 days).
An abdominal perineal resection was performed in 51
patients, a low anterior resection was performed in 50
patients, and an abdominal transanal resection was
performed in 2 patients.
Macroscopic Examination
The surgical specimens were opened on the anterior
wall and fixed in 10% buffered neutral formalin for 24
hours. The external surface of the surgical specimen
was painted with permanent ink. The whole tumor
and attached mesorectum were sliced serially in
3– 4-mm slices and the whole tumor was included for
histologic examination. For assessment of perirectal
lymph nodes, adipose tissue was removed after tumor
sampling and cleared in Carnoy solution over 24
hours.
Histologic Assessment
Tumor tissue blocks were embedded in paraffin, then
cut and stained with hematoxylin and eosin according
to standard procedure. All 103 irradiated rectal tumors
were reviewed by the same pathologist (H.B.). The
tumors were classified according to the World Health
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Organization classification of intestinal carcinoma27
and staged according to the TNM classification.28 Tu-
mor regression, degree of cytonuclear atypia, intensity
of the inflammatory reaction, and the extent of necro-
sis were recorded. Tumor regression was graded ac-
cording to a method described by Mandard et al. for
the assessment of pathologic response after neoadju-
vant chemoradiotherapy in esophageal carcinomas on
a scale from 1–5 based on the presence of residual
tumor cells and the extent of fibrosis.29 Grade 1 is
defined as the absence of residual tumor and fibrosis
extending through the different layers of the rectal
wall. Grade 2 is characterized by the presence of rare
residual tumor cells scattered throughout the fibrosis
(Fig. 1a). Grade 3 involves an increase in the number
of residual cells, but the fibrosis still predominates
(Fig. 1b). Grade 4 (Fig. 1c) demonstrates residual tu-
mor outgrowing the fibrosis and Grade 5 is character-
ized by the absence of any tumor regression (Fig. 1d).
Cytonuclear atypia were classified into mild, moder-
ate, or marked (Fig. 2). Tumor necrosis was graded as
1 when it represented  25% of the tumor mass, was
graded as 2 when it represented 25%–50% of the tu-
mor mass, was graded as 3 when it represented 50 –
75% of the tumor mass, and was graded as 4 when it
represented  75% of the tumor mass (Fig. 3). Intra-
tumor inflammatory reaction (mononuclear and gran-
ular cells) was graded as 0 when absent or mild, 1
when moderate, and 2 when extensive.
Downstaging was determined by comparing the
data regarding clinical and pathologic tumor stages.
Statistical Analysis and Follow-Up
The patients were followed for the development of
local recurrence and distant metastasis every 6
months for the first 2 years and every year thereafter.
A physical examination, serum CEA essay, chest X-ray,
and abdominal ultrasound or CT scan were included
in the follow-up procedure.
All statistical analyses were conducted using the
JUMP software (SAS, Cary, NC). A P value  0.05 was
considered statistically significant. The correlation be-
tween necrosis, cytonuclear atypia, inflammatory re-
action, and tumor regression grade (TRG) were stud-
‹
FIGURE 1. Tumor regression grading of rectal tumors in patients treated
preoperatively with radiotherapy. (1a) Tumor regression Grade (TRG) 2 is
characterized by the presence of rare residual tumor cells scattered through a
significant fibrosis. (1b) TRG3 involves an increased number of residual cells,
but the fibrosis still predominates. (1c) TRG4 demonstrates residual tumor cells
outgrowing the fibrosis. (1d) TRG5 is characterized by the absence of any tumor
regression.
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ied with the Pearson chi-square test. On the univariate
and multivariate analyses, overall survival (OS), dis-
ease-free survival (DFS), and local control were used
as the endpoints. On univariate analysis, survival
curves were estimated according to the Kaplan–Meier
method for the following pathologic variables: pT clas-
sification, pN classification, tumor types, TRG, necro-
sis, inflammation, and cytonuclear atypia. The statis-
tical significance of their differences was estimated
using the log-rank test. To increase the number of
patients per group, the categories of the various
pathologic variables also were combined for theses
analyses: pT1-2 versus pT3-4; well and moderately
differentiated adenocarcinomas versus poorly differ-
entiated and mucinous carcinomas; responder group
(TRG2– 4) versus nonresponder group (TRG5); necro-
sis  25% versus necrosis  25%; absent, mild, or
moderate inflammatory reaction versus extensive in-
flammatory reaction; and mild or moderate cyto-
nuclear atypia versus marked cytonuclear atypia.
The multivariate survival analysis according to the
Cox proportional hazards model was constructed by
backward elimination of the following variables: pT
classification, pN classification, TRG, necrosis, inflam-
mation, and cytonuclear atypia. Patient age was not
included in this model because it was not found to be
statistically significant on the univariate analysis.
RESULTS
Pathologic Findings
Of the 103 rectal tumors 2 were pT1 (2%), 21 were pT2
(20%), 66 were pT3 (64%), and 14 were pT4 (14%). Of
all the patients, 44 (43%) had their tumor downstaged
at the time of pathologic examination (Table 1). Re-
gional lymph node metastases were found in 55 pa-
tients (53%), but there was no reported lymph node
downstaging.
The histologic variables analyzed and their corre-
lation with survival and local control are summarized
FIGURE 2. (a) Mild, (b) moderate, or (c) marked cytonuclear atypia in rectal
carcinoma treated with preoperative radiotherapy.
FIGURE 3. Significant tumor necrosis involving  75% of the tumor tissue
in a rectal carcinoma from a patient treated with preoperative radiotherapy.
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in the Table 2. Tumors were classified as well, moder-
ately, and poorly differentiated adenocarcinoma in
25%, 40%, and 13% respectively, of the patients and
the remaining 22% of patients were determined to
have mucinous carcinomas. Mucinous carcinomas
were found to be associated significantly with ad-
vanced pT classification (pT3-4; P  0.04).
None of the 103 tumors demonstrated complete
tumor regression. Partial tumor regression (TRG2-4)
was noted in 79% and no regression (TRG5) was noted
in 21% of the tumors. Of the tumors that did demon-
strate regression, 20% were TRG2, 39% were TRG3,
and 20% were TRG4. Advanced pT3-4 tumors fre-
quently demonstrated no tumor regression (TRG5) (P
 0.01).
We found a strong correlation between the differ-
ent levels of tumor regression and necrosis. Tumors
with  25% necrotic cells were found to have a better
histologic tumor regression than tumors with  25%
necrotic cells (P  0.012) (Table 3). A significant asso-
ciation was observed between cytonuclear atypia and
tumor response, with TRG5 being highest in tumors
with mild atypia and lowest in tumors with marked
atypia (P  0.010) (Table 3). When we analyzed the
group of tumors demonstrating a partial histologic
tumor regression (TRG2– 4) and those without histo-
logic tumor regression (TRG5) (Table 4), the same
correlation between necrosis, cytonuclear atypia, and
tumor response was observed. We also found a signif-
icant correlation between a partial tumor response
and the presence of extensive inflammation (P
 0.011) (Table 4).
Survival Analysis
During follow-up (median, 40 months) 29 patients
(28.2%) developed distant metastasis and 8 patients
(7.8%) developed local recurrence. Forty-five patients
died, 34 of rectal carcinoma. The median actuarial OS
and DFS both were 52 months. The actuarial local
recurrence rates at 2 years and 5 years were 6.4% and
7.6%, respectively. The type of surgical resection did
not appear to have any influence on survival.
The influence of the various pathologic variables
on survival and local control by univariate analysis is
summarized in Table 2. The median actuarial OS was
significantly lower in patients with lymph node me-
tastases (P  0.0001, log-rank test) and in patients
with poorly differentiated or mucinous carcinoma (P
 0.03, log-rank test). There was a trend toward his-
tologic response (TRG) correlating with OS (P  0.06,
log-rank test). When grouped together, responders
(TRG2, 3, and 4) demonstrated a significantly better
overall survival than nonresponders (TRG5) (P  0.02,
log-rank test) (Fig. 4). The median actuarial DFS was
significantly lower in patients with advanced pT dis-
ease (pT3-4) (P  0.03, log-rank test) and those with
lymph node metastases (P  0.0004, log-rank test). A
significant correlation was found between the differ-
ent grades of tumor response and DFS (P  0.04,
log-rank test) (Fig 5). The DFS was longer in respond-
ers (TRG2, 3, and 4) compared with nonresponders
(TRG5) (P  0.03, log-rank test). Local control ap-
peared to be better in responders (TRG2-4) compared
with nonresponders (TRG5) (P  0.02, log-rank test).
Tumor downstaging did not appear to correlate with
survival.
Patients demonstrating more tumor necrosis
tended to survive longer compared with patients who
did not, but this difference did not reach statistical
significance. Features such as cytonuclear atypia and
inflammatory reaction did not appear to correlate
with survival.
Using multivariate survival analysis we found that
pT was an independent prognostic factor for OS. pT
and pN were found to be independent prognostic
factors for DFS whereas with regard to local control,
only TRG remained an independent prognostic indi-
cator.
DISCUSSION
Both local recurrence and distant metastasis after sur-
gery remain major problems in the curative approach
to rectal carcinoma. Preoperative radiation therapy
has been shown to reduce the incidence of local re-
currence and in some trials has been reported to im-
prove survival.7–18,22–24,30 –34 Therefore, this treatment
modality currently is considered part of a standard
approach.35 However, randomized trials involving
preoperative radiotherapy and surgery alone are diffi-
cult to compare because there is considerable varia-
tion in the irradiation techniques between the studies.
Discrepancies arising from these trials also may be
due to different factors such as heterogeneity in clin-
ical stages; the absence of a standardized method
for pathologic analysis; and confusion between the
pathologic stages, downstaging, and tumor regression.
TABLE 1
Tumor Downstaging in a Series of 103 Rectal Carcinoma Patients
who were Treated with Preoperative Radiotherapy
cT2 cT3 cT4 Total
pT1 1 1 0 2 (2%)
pT2 0 19 2 21 (20%)
pT3 0 45 21 66 (64%)
pT4 0 4 9 14 (14%)
Total 1 70 32 103 (100%)
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To our knowledge to date, very few studies regarding
the histologic manifestations of tumor response to
preoperative radiotherapy have been reported and few
provide a detailed analysis of tumor regression. The
extent of the histologic response to preoperative ra-
diotherapy varies from tumor to tumor, with some
being more radioresponsive than others. Therefore,
a systematic pathologic workup is essential if one
wishes to compare the results of preoperative radio-
therapy between different groups.
We have reported previously that preoperative
HART, an innovative schedule of radiotherapy for pa-
tients with rectal carcinoma, is feasible, improves the
radical resection rate, and induces a significantly
TABLE 2














Pathologic tumor stage (grouped) 0.18 0.03 0.7
Early pT (pT1 and pT2)
Advanced pT (pT3 and pT4)
Pathologic lymph node stage 0.0017 0.0004 0.4
pN 55 53%
pN0 48 47%
Tumor differentiation 0.06 0.3 0.4
Well differentiated 26 25%
Moderately differentiated 41 40%
Poorly differentiated 13 13%
Mucinous carcinoma 23 22%
Tumor differentiation (grouped) 0.03 0.7 0.3
Well and moderately differentiated 67 65%
Poorly differentiated and mucinous carcinoma 36 35%






TRG (grouped) 0.02 0.03 0.02
Responder group (TRG 2, 3, and 4) 81 79%
Nonresponder group (TRG 5) 22 21%
OS: overall survival; DFS: disease-free survival; TRG: tumor regression grade.
TABLE 3
Correlation between Rectal Carcinoma Tumor Regression Grades 2, 3, 4, and 5 Treated Preoperatively with Radiotherapy and Tumor Necrosis,
Inflammation, and Cytonuclear Atypia
TRG
Necrosis Inflammation Cytonuclear atypia
< 25% > 25% Absent or mild Moderate Extensive Mild Moderate Marked
P  0.012 P  0.131 P  0.010
TRG2 20% 17% 15% 23% 15% 10% 18% 22%
TRG3 27% 58% 27% 46% 39% 30% 32% 45%
TRG4 25% 17% 22% 22% 23% 0% 23% 25%
TRG5 28% 8% 36% 9% 23% 60% 27% 8%
TRG: tumor regression grade.
1126 CANCER February 15, 2002 / Volume 94 / Number 4
lower acute toxicity compared with postoperative ra-
diotherapy.25,26 Our current prospective series in-
cludes only patients with locally advanced rectal car-
cinoma who were treated with the same schedule of
preoperative HART. The objective of the current study
was to evaluate the histologic manifestations of tumor
response and its correlation with OS, DFS, and local
control. Using a standardized method, we analyzed
specifically tumor regression and histologic parame-
ters such as necrosis, inflammatory reaction, and cy-
tonuclear atypia that can influence tumor regression.
One of the first simple and reproducible grading
systems for tumor regression was described by Man-
dard et al. in patients with esophageal carcinoma who
were treated preoperatively by chemoradiotherapy.29
More recently, Dworak et al. proposed a tumor regres-
sion grading system for rectal carcinoma (Grade 0 for
no tumor regression, Grade 1 for dominant tumor,
and Grade 3 for tumor with few cells) and demon-
strated that 16 of 17 patients treated with preoperative
chemoradiotherapy achieved a significant response,
but no patient achieved complete regression of tu-
mor.36 Using the tumor regression grade elaborated by
Mandard et al., Bozzetti et al. reported a  50% re-
sponse (TRG1, 2, and 3) in 13 of 20 patients undergo-
ing preoperative radiotherapy for rectal carcinoma,
with 1 patient achieving complete regression.37 In the
current series, we also used the grading system of
Mandard et al. for tumor regression and observed that
79% of the patients achieved a partial tumor regres-
sion and that 21% of patients demonstrated no evi-
dence of tumor regression. In contrast to some stud-
ies, we did not observe a single case of complete
tumor regression in patients with rectal carcinoma
after preoperative radiotherapy.7,30,38 This might be
explained by the short delay between the end of the
radiotherapy and surgery in the schedule used in the
current study and also by the fact that only patients
with locally advanced stages of rectal carcinoma were
included in the current study compared with other
studies in which a significant proportion of patients
TABLE 4
Correlation between Tumor Responders versus Nontumor Responders and Necrosis, Inflammation, and Cytonuclear Atypias
TRG
Necrosis Inflammation Cytonuclear atypias
P  0.022 P  0.011 P  0.000
< 25% > 25% Absent Moderate Extensive Mild Moderate Marked
PR (TRG2-4) 72% 92% 64% 91% 77% 40% 73% 92%
NR (TRG5) 28% 8% 36% 9% 23% 60% 27% 8%
TRG: tumor regression grade; PR: partial response; NR: no response.
FIGURE 4. Overall survival (OS) in the responder group (tumor regression
Grades [TRG] 2, 3, and 4) was better than in the nonresponder group (TRG 5)
(P  0.02, log-rank test).
FIGURE 5. A significant correlation was observed between tumor regression
grade (TRG) and disease-free survival (DFS) in patients with rectal carcinoma
who were treated with preoperative radiotherapy (P  0.03, log-rank test).
Tumor Regression in Rectal Carcinoma/Bouzourene et al. 1127
with cT1-T2 tumors was included.30 To our knowl-
edge, there have been no reports to date of complete
tumor regression occurring when surgery is per-
formed within 1 week after the end of radiotherapy, a
finding that is consistent with our own data.10,12,14,16,17,19
In contrast, in studies with a longer interval between
the end of radiotherapy and surgery ( 10 days), com-
plete histologic regression was reported in 2–11% of
the patients.7,30,38 – 41 However, to diagnose complete
tumor regression, the entire tumor region must be
sampled and carefully screened for any small surviv-
ing foci of carcinoma by thorough histologic workup.
Results regarding a possible correlation between
survival and tumor regression are contradictory. The
results of the current study indicate that the respond-
ers (TRG2– 4) have better OS, DFS, and local control
than nonresponders (TRG5). Moreover, residual tu-
mor cell density was found to be correlated highly
with DFS; however, it remains an independent prog-
nostic indicator only for local control. Some patho-
logic parameters such as necrosis, degree of cyto-
nuclear atypia, and inflammation were, as one could
expect, found to be related closely to TRG and there-
fore were not considered to be independent and were
not determined to be correlated significantly with out-
come on multivariate analysis. Berger et al. found that
OS and DFS rates for patients with a complete histo-
logic response are better but that residual tumor cell
density is not a prognostic factor.30 Kaminsky-Forrett
et al. demonstrated that patients with significant tu-
mor regression, (i.e., no residual tumor cells or only
rare foci of residual cells localized in the submucosa
and/or invaded muscularis propria) have a signifi-
cantly higher cancer specific survival rate compared
with patients without tumor regression.39
We found, both in the current series and in accor-
dance with the literature,30,32,33,39 that prognosis re-
mained dependent on pN status for OS, and pT and
pN status for DFS, even after radiotherapy.
Tumor downstaging has been regarded as a
marker for tumor radiosensitivity and has been re-
ported to be an important prognostic factor.30,39,42
However, a recent review of randomized trials of pre-
operative radiotherapy versus surgery alone demon-
strated that very few available objective and controlled
data (i.e., after pathologic review) concerning down-
staging rates were available.43 In the current series, we
observed a very high rate of downstaging (43%) but
the OS and DFS in patients whose tumors were down-
staged after preoperative radiotherapy did not appear
to improve compared with patients whose tumors
were not downstaged. The discrepancies between the
current study results and those from previous studies
may be due to the absence of a clear definition of
tumor downstaging and a frequent confusion of it
with TRG. In fact, in the current series, there was not
an apparently perfect correlation between tumor
downstaging and tumor regression, because several
tumors remained at the same pathologic stage after
radiotherapy even if the tumor cell density signifi-
cantly decreased and necrosis increased.
Results concerning lymph node downstaging also
are variable in the literature. In the current series, we
found no downstaging of lymph node metastases after
preoperative radiotherapy. In contrast, we observed a
higher incidence of positive lymph nodes on patho-
logic examination than was yielded by clinical N clas-
sification (53% vs. 27%). However, we believe this
finding merely indicates the lack of reliability of
preoperative staging by radiologic techniques. More-
over, our method of lymph node dissection by clearing
mesorectal fat significantly facilitated the detection of
lymph node metastases. In the literature data, a re-
duced number of lymph node metastases after pre-
operative radiotherapy was reported in some stud-
ies8,16,18,38,42,44 whereas in other studies no significant
difference was found.12,17,32
CONCLUSIONS
Based on this comprehensive pathologic review of 103
surgical specimens of locally advanced rectal tumors
after preoperative HART, we conclude that there is a
strong correlation between TRG and outcome. We
tentatively raise the hypothesis that TRG can be used
to stratify patients in trials, raising questions regarding
the need for postoperative adjuvant treatment.
REFERENCES
1. Bosset JF, Arbez-Gindre F, Pelissier E, Mantion G, Camelot
G, Gillet M, et al. Facteurs anatomo-pathologiques de
pronostic des cancers du rectum. Etude mono- et multifac-
torielle. Gastroenterol Clin Biol 1986;10:728 –35.
2. Minsky BD, Mies C, Recht A, Rich T, Chaffey J. Resectable
adenocarcinoma of the rectosigmoid and rectum. Patterns
of cancer failure and survival. Cancer 1988;61:1408 –16.
3. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ,
Johnston D, et al. Role of circumferential margin involve-
ment in the local recurrence of rectal cancer. Lancet 1994;
344:707–11.
4. Quirke P, Durdey P, Dixon MF, Rich T, Chaffey J. Local
recurrence of rectal adenocarcinoma due to inadequate sur-
gical resection. Histopathological study of lateral tumour
spread and surgical excision. Lancet 1986;1:996 – 8.
5. Balslev I, Pedersen M, Teglbjaerg PS, Hanberg-Soerensen F,
Bone J, Jacobsen NO, et al. Postoperative radiotherapy in
Dukes’ B and C carcinoma of the rectum and rectosigmoid.
A randomized multicenter study. Cancer 1986;58:22– 8.
6. Duncan W. Adjuvant radiotherapy in rectal cancer: the MRC
trials. Br J Surg 1985;72(Suppl):S59 – 62.
1128 CANCER February 15, 2002 / Volume 94 / Number 4
7. Gerard A, Buyse M, Nordlinger B, Loygue J, Pene F, Kempf P,
et al. Preoperative radiotherapy as adjuvant treatment in
rectal cancer. Final results of a randomized study of the
European Organization for Research and Treatment of Can-
cer (EORTC). Ann Surg 1988;208:606 –14.
8. Horn A, Morild I, Dahl O. Tumour shrinkage and downstag-
ing after preoperative radiation of rectal adenocarcinoma.
Radiother Oncol 1990;18:19 –28.
9. Rider WD, Palmer JA, Mahoney LJ, Robertson CT. Preoper-
ative irradiation in operable cancer of the rectum: report of
the Toronto trial. Can J Surg 1977;20:335– 8.
10. Stockholm Colorectal Cancer Study Group. Preoperative
short-term radiation therapy in operable rectal carci-
noma. A prospective randomized trial. Cancer 1990;66:
49 –55.
11. Glimelius B, Isacsson U, Jung B, Pahlam L. Radiotherapy in
addition to radical surgery in rectal cancer-evidence for a
dose-response effect favouring preoperative treatment. Int J
Radiat Oncol Biol Phys 1997;15:281–7.
12. Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE.
Long term results of a randomized trial of short-course low
dose adjuvant preoperative radiotherapy for rectal cancer:
reduction in local treatment failure. Eur J Cancer 1994;30A:
1602– 6.
13. Reis Neto JA, Quilici FA, Reis JA. A comparison of nonop-
erative vs. preoperative radiotherapy in rectal carcinoma. A
10-year randomized trial. Dis Colon Rectum 1989;32:702–10.
14. Stockholm Colorectal Cancer Study Group. Randomized
study on preoperative radiotherapy in rectal carcinoma.
Ann Surg Oncol 1996;3:423–30.
15. Swedish Rectal Cancer Trial. Local recurrence rate in a ran-
domized multicenter trial of preoperative radiotherapy
compared with operation alone in resectable rectal carci-
noma. Eur J Surg 1996;162:397– 402.
16. Swedish Rectal Cancer Trial. Improved survival with preop-
erative radiotherapy in resectable rectal cancer. N Engl
J Med 1997;336:980 –7.
17. Marsh PJ, James RD, Shofield PF. Adjuvant preoperative
radiotherapy for locally advanced rectal carcinoma. Results
of a prospective randomized trial. Dis Colon Rectum 1994;
37:1205–14.
18. Medical Research Council Rectal Cancer Working Party.
Randomised trial of surgery alone versus radiotherapy fol-
lowed by surgery for potentially operable locally advanced
rectal cancer. Lancet 1996;348:1605–10.
19. Higgins GA, Humphrey EW, Dwight RW, Roswit B, Lee LE Jr.,
Keehn RJ. Preoperative radiation and surgery for cancer of
the rectum. Veterans Administration Surgical Oncology
Group Trial II. Cancer 1986;58:352–9.
20. Second Report of an MRC Working Party. The evaluation of
low dose pre-operative X-ray therapy in the management of
operable rectal cancer: results of a randomly controlled trial.
Br J Surg 1984;71:21–5.
21. Coia LR, Gunderson LL, Haller D, Hoffman J, Mohiuddin M,
Tepper JE, et al. Outcomes of patients receiving radiation for
carcinoma of the rectum. Results of the 1988-1989 patterns
of care study. Cancer 1999;86:1952– 8.
22. Reed WP, Garb JL, Stark AJ, Chabot JR, Friedmann P. 10-year
results of preoperative radiotherapy in treatment of rectal
carcinoma. Chirurg 1996;67:621– 4.
23. Roswit B, Higgins GA, Keehn RJ. Preoperative irradiation for
carcinoma of the rectum and rectosigmoid colon: report of
a National Veterans Administration randomized study. Can-
cer 1975;35:1597– 602.
24. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone
M. Preoperative radiotherapy for resectable rectal cancer: a
meta-analysis. JAMA 2000;284:1008 –15.
25. Coucke PA, Sartorelli B, Cuttat JF, Jeanneret W, Gillet M,
Mirimanoff RO, et al. The rationale to switch from post-
operative hyperfractionated accelerated radiotherapy to
preoperative hyperfractionated accelerated radiotherapy
in rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:
181– 8.
26. Coucke PA. On behalf of the participants to Trial 93-01:
curative resection rate after Hyperfractionated Accelerated
Radiotherapy (HART) immediately followed by surgery in
locally advanced rectal cancer. Radiother Oncol 1997;
43(Suppl 2):S45.
27. World Health Organization. International histological clas-
sification of tumors. Histological typing of intestinal tu-
mours. 2nd edition. Berlin: Springer-Verlag, 1989.
28. Sobin LH, Wittekind Ch., editors. International Union
Against Cancer. TNM classification of malignant tumours.
5th edition. New York: John Wiley & Sons, Inc., 1997.
29. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-
Amar M, Petiot JF, et al. Pathologic assessment of tumor
regression after preoperative chemoradiotherapy of esoph-
ageal carcinoma. Clinicopathologic correlations. Cancer
1994;73:2680 – 6.
30. Berger C, de Muret A, Garaud P, Chapet S, Bourlier P,
Reynaud-Bougnoux A, et al. Preoperative radiotherapy
(RT) for rectal cancer: predictive factors of tumor down-
staging and residual tumor cell density (RTCD): prognos-
tic implications. Int J Radiat Oncol Biol Phys 1997;37:619 –
27.
31. Pahlam L, Glimelius B. The value of adjuvant radio (chemo)
therapy for rectal cancer. Eur J Cancer 1995;31A:1347–50.
32. Gerard JP, Chapet O, Morignat E, Romestaing P, Mornex F,
Acharki A. Preoperative radiotherapy of rectal cancer. The
Lyon experience 1985-1996. Prognostic study a propos of
312 patients. Ann Chir 1999;53:1003–10.
33. Luna-Perez P, Trejo-Valdivia B, Labastida S, Garcia-Al-
varado S, Rodriguez DF, Delgado S. Prognostic factors in
patients with locally advanced rectal adenocarcinoma
treated with preoperative radiotherapy and surgery. World
J Surg 1999;23:1069 –74.
34. Petersen S, Hellmich G, Baumann M, et al. Brief preopera-
tive radiotherapy in surgical therapy of rectal carcinoma.
Long term outcome of a prospective randomized study.
Chirurg 1998;69:759 – 65.
35. NIH Consensus Conference. Adjuvant therapy for patients
with colon and rectal cancer. JAMA 1990;19:1444 –50.
36. Dworak O, Keilholz L, Hoffmann A. Pathological features of
rectal cancer after preoperative radiochemotherapy. Int J
Colorectal Dis 1997;12:19 –23.
37. Bozzetti, F, Andreola, S, Rossetti C, Zucali R, Meroni E,
Baratti D, et al. Preoperative radiotherapy for resectable
cancer of the middle-distal rectum: its effect on the pri-
mary lesion as determined by endorectal ultrasound us-
ing flexible echo colonoscope. Int J Colorectal Dis 1996;
11:283– 6.
38. Dahl O, Horn A, Morild I, Halvorsen JF, Odland G, Reinert-
sen S, et al. Low-dose preoperative radiation postpones
recurrences in operable rectal cancer. Results of a random-
ized multicenter trial in Western Norway. Cancer 1990;66:
2286 –94.
Tumor Regression in Rectal Carcinoma/Bouzourene et al. 1129
39. Kaminsky-Forrett MC, Conroy T, Luporsi E, Peiffert D, La-
peyre M, Boissel P, et al. Prognostic implication of down-
staging following preoperative radiation for operable T3-T4
rectal cancer. Int J Radiat Oncol Biol Phys 1998;42:935– 41.
40. Mendenhall WM, Bland EM, Copeland EM, Summers GE,
Pfaff WW, Souba WW, et al. Does preoperative radiation
therapy enhance the probability to local control and survival
in high risk distal cancer? Ann Surg 1992;215:696 –705.
41. Mohiuddin M, Marks G. High dose preoperative irradiation
for cancer of the rectum. Int J Radiat Oncol Biol Phys 1991;
20:37– 43.
42. Graf W, Dahlberg M, Osman MM, Homberg L, Pahlam L,
Grimelius B. Short-term preoperative radiotherapy results
in down-staging of rectal cancer: a study of 1316 patients.
Radiother Oncol 1997;43(2):133–7.
43. Wheeler JM, Warren BF, Jones AC, Mortensen NJ. Preoper-
ative radiotherapy for rectal cancer: implications for sur-
geons, pathologists and radiologists. Br J Surg 1999;86:1108 –
20.
44. Ahmad NR, Nagle D. Long-term results of preoperative ra-
diation therapy alone for stage T3 and T4 rectal cancer. Br J
Surg 1997;84:1445– 8.
1130 CANCER February 15, 2002 / Volume 94 / Number 4
